BioAge Labs News

Morgan Stanley Downgrades BioAge Labs to Underweight From Overweight, Slashes Price Target to $5 From $40

MT NewswiresDec 10, 2024 06:23 ET

Citigroup Downgrades BioAge Labs to Neutral From Buy, Adjusts Price Target to $7 From $45

MT NewswiresDec 9, 2024 07:29 ET

Morgan Stanley Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $40

Moomoo NewsDec 9, 2024 06:31 ET

Bioage Labs Analyst Ratings

BenzingaDec 9, 2024 06:27 ET

Jefferies Downgrades Bioage Labs to Hold, Lowers Price Target to $7

BenzingaDec 9, 2024 06:26 ET

Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA), Acadia Healthcare (ACHC) and Bicara Therapeutics Inc. (BCAX)

TipRanksDec 9, 2024 06:22 ET

Morgan Stanley Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $40

Moomoo NewsNov 8, 2024 09:31 ET

Morgan Stanley Keeps Their Buy Rating on BioAge Labs, Inc. (BIOA)

TipRanksNov 8, 2024 09:29 ET

Citi Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $45

Moomoo NewsOct 22, 2024 06:31 ET

Citi Initiates BioAge Labs(BIOA.US) With Buy Rating, Announces Target Price $45

Moomoo NewsOct 21, 2024 08:33 ET

Bioage Labs Analyst Ratings

BenzingaOct 21, 2024 06:57 ET

Jefferies Initiates BioAge Labs(BIOA.US) With Buy Rating, Announces Target Price $42

Moomoo NewsOct 21, 2024 05:33 ET

Morgan Stanley Initiates BioAge Labs(BIOA.US) With Buy Rating, Announces Target Price $40

Moomoo NewsOct 21, 2024 05:33 ET

BioAge Labs Initiated With an Overweight at Morgan Stanley

TipRanksOct 21, 2024 05:22 ET

BioAge Labs Initiated With a Buy at Jefferies

TipRanksOct 21, 2024 05:22 ET

BioAge Labs, Inc.: Promising Developments and Strategic Partnerships Lead to Buy Rating

TipRanksOct 21, 2024 05:19 ET